A new report from the Association of the British Pharmaceutical Industry (ABPI) shows that the UK has been leading the rest of Europe in the number of early-phase and phase 2 trials as well as in the number of oncology trials, but the country appears to fall behind global competitors for phase 3 trials.

The UK ranked second behind the U.S. for phase 2 trials, with 268 UK-based trials started in 2018 — the most recent data studied — compared to 1,021 trials initiated in the U.S. during the same year. And while the UK continues to lead Europe in early-stage trials, the country’s phase 1 trial activity declined to 95 trials in 2018 compared to 117 phase 1 trials in 2017.

Additionally, the UK ranks third in Europe behind Germany and Spain in the number of phase 3 clinical trials, with only 292 trials initiated in the UK in 2018 compared to 315 in Germany and 308 in Spain. The report discovered that oncology continues to be UK’s strongest research area, highlighted by 226 cancer trials initiated in the country in 2018. Germany follows in oncology research with 221 cancer studies initiated in 2018.

Read the full report here: https://bit.ly/2FgOsHr.